Supriya Lifescience
SUPRIYA · Pharma > Pharmaceuticals & Drugs · Chairman: Satish Waman Wagh · MD: Satish Waman Wagh · Listing date: Dec. 29, 2021

Stock Price vs Company Growth
1d
0.9%
1w
5.8%
1m
9.9%
3m
16.2%
6m
4.7%
1y
0.9%
all
6.8%

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

₹ 625 0.9%
617
775
Company Overview

Sales
735 Cr
Growth: 12.5%
Profit after Tax
185 Cr
Growth: 1.6%
Small Cap
5,028 Cr
P/E: 27.1x
Industry P/E: 27.8x
Fundamentals

Sales (Cr) ₹ 735
Growth 12.5%
EBITDA 35.9%
P/S 6.8x
Dividend 0.1%
P/E 27.1x
Book Value ₹ 2
PEG Ratio 2.2x
ROE 999.0%
P/B N/A
Shareholding Pattern

Institutions
Promoters
Others
Increase    Decrease    No change
Company Profile Detailed

The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (APIs), with a focus on research and development. The company has niche product offerings of various APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic.
Investors (5)
Followers (1)